Compounds > ammonium-trichloro(dioxoethylene-o-o--)tellurate

ammonium-trichloro(dioxoethylene-o-o--)tellurate and Dermatitis--Atopic

ammonium-trichloro(dioxoethylene-o-o--)tellurate has been researched along with Dermatitis--Atopic* in 1 studies

Other Studies

1 other study(ies) available for ammonium-trichloro(dioxoethylene-o-o--)tellurate and Dermatitis--Atopic

Article	Year
The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis. Journal of dermatological science, 2008, Volume: 50, Issue:3 The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNgamma and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD. Topics: Adjuvants, Immunologic; Child; Dermatitis, Atopic; Ethylenes; Humans; In Vitro Techniques; Interleukin-10; p38 Mitogen-Activated Protein Kinases	2008

Article

Year

The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis.

Journal of dermatological science, 2008, Volume: 50, Issue:3

The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNgamma and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Topics: Adjuvants, Immunologic; Child; Dermatitis, Atopic; Ethylenes; Humans; In Vitro Techniques; Interleukin-10; p38 Mitogen-Activated Protein Kinases

2008